Andere Sprachen Satellos Bioscience Inc.

Aktien

A3CSSM

CA80401L3083

MSCL

Markt geschlossen - Toronto S.E. Andere Börsenplätze 21:53:03 28.06.2024			% 5 Tage	% 1. Jan.
0.52 ^CAD	-3.70%		-11.86%	+20.93%

28.05.	Satellos Bioscience Inc. kündigt Gründung eines klinischen Beirats an	CI
14.05.	Satellos Bioscience Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Satellos Announces Presentation at Parent Project Muscular Dystrophy 30th Annual Conference	16:07
Satellos Bioscience Inc. Brief: Adds Trial will evaluate the safety and pharmacokinetic properties of SAT-3247 in healthy human volunteers	27.06.
Satellos Bioscience Inc. Brief: Co Says intends to submit a regulatory package in July to initiate a first-in-human Phase 1 clinical trial, in Q3 2024	27.06.
Satellos Bioscience Inc. Brief: Says CEO Frank Gleeson Participating at Parent Project Muscular Dystrophy (PPMD) 30th Annual Conference	27.06.
Satellos Announces Presentation at Parent Project Muscular Dystrophy (PPMD) 30th Annual Conference	27.06.
Satellos Bioscience Forms Advisory Board to Advance SAT-3247 in Duchenne Muscular Dystrophy Treatment	28.05.
Satellos Bioscience Inc. Brief: Announcing Formation of Clinical Advisory Board to Support Advancing SAT-3247 in Clinical Trial Development for Duchenne Muscular Dystrophy	28.05.
Satellos Announces Formation of Clinical Advisory Board to Support Advancing SAT-3247 in Clinical Trial Development for Duchenne Muscular Dystrophy	28.05.
Satellos Bioscience Inc. Announces Formation of Clinical Advisory Board	28.05.
Satellos Bioscience Inc. Opens the Market	15.05.
Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders	14.05.
Satellos Bioscience: Q1 Earnings Snapshot	14.05.
Satellos Bioscience Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14.05.
Satellos Bioscience Q1 Loss Widens Due To Higher Expenses; But Says "On track" to initiate Phase 1 First-in-human Clinical Trials Mid-2024	14.05.
Satellos Bioscience Announces Q1 2024 Financial Results and Operational Highlights	14.05.
Satellos to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	08.04.
Satellos Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.03.
Satellos Bioscience: Q4 Earnings Snapshot	27.03.
Satellos Bioscience Announces FY 2023 Results	27.03.
Satellos Bioscience Announces 2023 Year End Financial Results and Operational Highlights	27.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Satellos Bioscience Inc.

Aktien

A3CSSM

CA80401L3083

MSCL

Andere Sprachen

Filter